InSilicoMinds

🚀 𝐔𝐧𝐥𝐨𝐜𝐤 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐋𝐚𝐭𝐞𝐬𝐭 𝐔𝐊 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐨𝐧 𝐈𝐧 𝐒𝐢𝐥𝐢𝐜𝐨 𝐓𝐫𝐢𝐚𝐥𝐬! We are excited to share the key findings from the newly released report titled "𝑼𝒏𝒍𝒐𝒄𝒌𝒊𝒏𝒈 𝒕𝒉𝒆 𝑷𝒐𝒘𝒆𝒓 𝒐𝒇 𝑪𝒐𝒎𝒑𝒖𝒕𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝑴𝒐𝒅𝒆𝒍𝒊𝒏𝒈 𝒂𝒏𝒅 𝑺𝒊𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝑨𝒄𝒓𝒐𝒔𝒔 𝒕𝒉𝒆 𝑷𝒓𝒐𝒅𝒖𝒄𝒕 𝑳𝒊𝒇𝒆𝒄𝒚𝒄𝒍𝒆 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆𝒔." Authored by leading experts from institutions like the The University of Manchester, Avicenna Alliance, and the #Medicines and #Healthcare Products #RegulatoryAgency, this comprehensive analysis addresses how in silico trials (ISTs) can revolutionize our approach to drug and device development. It's exciting to see thought leaders like Mark Palmer, M.D., Ph.D., Marc Horner, Ph.D., and Thierry Marchal contributing their invaluable insights to this impactful work. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 🔑 Utilization of ISTs can lead to up to 𝟲𝟬% 𝐟𝐚𝐬𝐭𝐞𝐫 development of new drugs and medical devices. As an example, Medtronic reported saving $𝟭𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 and reducing market access time by two years for its Micra leadless pacemaker through in silico simulations! 🌍 By 2025, manufacturers are expected to apply in silico methods in 𝟮𝟱% 𝗼𝗳 𝗻𝗲𝘄 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 and 𝟱𝟬% 𝗼𝗳 𝗻𝗲𝘄 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲𝘀, representing a 𝗴𝗹𝗼𝗯𝗮𝗹 𝗺𝗮𝗿𝗸𝗲𝘁 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝗲𝗱 𝗮𝘁 $𝟭𝟬𝟵 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 for IST-enabled solutions! 📈 There’s an increasing recognition from regulatory bodies. The FDA and European Medicines Agency are both promoting modeling and simulation techniques to enhance approval processes, showing that the tide is turning towards embracing #digitalevidence in clinical evaluations. 🔬 𝘛𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘷𝘦 𝘐𝘮𝘱𝘢𝘤𝘵 𝘰𝘯 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘛𝘳𝘪𝘢𝘭𝘴: In silico trials are designed to #refine, #reduce, and occasionally #replace conventional human #clinicaltrials. They enable testing on virtual populations that can account for variability and complex patient characteristics, making it easier to predict #safety and #efficacy outcomes across diverse groups. ✨ There's so much more in this report than we can cover in a post! We encourage you to dive into the details and see how in silico technologies are set to reshape the future of #healthcare. 📚➡️ Read the full report here! https://lnkd.in/guvx3HD2 InSilicoTrials #InSilicoMinds #LifeSciences #Innovation #ClinicalTrials #ComputationalModeling #RegulatoryScience

Proud to share that our Founder and CEO, Nirnith Devireddy has been appointed as the Co-Chair of the Avicenna AI Task Force! 🚀 Nirnith’s expertise and visionary leadership in AI-driven healthcare will be instrumental in guiding the Task Force towards achieving its goals. Congratulations, Nirnith, on this well-deserved recognition! ✨️ InSilicoTrials Avicenna Alliance #AI #ArtificialIntelligence #Leadership #InSilicoMinds #HealthcareInnovation

𝑬𝒙𝒄𝒊𝒕𝒊𝒏𝒈 𝑵𝒆𝒘𝒔 𝒊𝒏 𝒕𝒉𝒆 𝑾𝒐𝒓𝒍𝒅 𝒐𝒇 𝑰𝒏 𝑺𝒊𝒍𝒊𝒄𝒐 𝑻𝒓𝒊𝒂𝒍𝒔! 🌐 We at InSilicoMinds are thrilled to spotlight the incredible progress in computational modeling and simulation, showcased by the recent ENRICHMENT project—a groundbreaking collaboration between FDA and Dassault Systèmes. ✨️ This project highlights the power of in silico clinical trials in #revolutionizing the development of new medical products. By significantly #reducing the time from design to patient access, it exemplifies how #technology can lead to better, faster, and safer #medical innovations. 📈 Kudos to all the brilliant minds who contributed! 🎉 InSilicoTrials #InSilicoMinds #FDA #ComputationalModeling #InSilicoClinicalTrials #MedicalInnovation #DigitalHealth

𝐈𝐧𝐒𝐢𝐥𝐢𝐜𝐨𝐌𝐢𝐧𝐝𝐬 𝐰𝐚𝐬 𝐡𝐨𝐧𝐨𝐫𝐞𝐝 𝐭𝐨 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞 𝐢𝐧 𝐂𝐚𝐩𝐠𝐞𝐦𝐢𝐧𝐢 𝐀𝐈𝐄'𝐬 𝐩𝐫𝐞𝐬𝐭𝐢𝐠𝐢𝐨𝐮𝐬 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 5.0 𝐑𝐨𝐮𝐧𝐝𝐭𝐚𝐛𝐥𝐞 𝐢𝐧 𝐇𝐲𝐝𝐞𝐫𝐚𝐛𝐚𝐝 𝐨𝐧 𝐀𝐮𝐠𝐮𝐬𝐭 6, 2024. 🧑🔬💊 𝗖𝗮𝗽𝗴𝗲𝗺𝗶𝗻𝗶’𝘀 𝗔𝗽𝗽𝗹𝗶𝗲𝗱 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲 (𝗔𝗜𝗘) is a global platform for innovation. It brings together a framework for action, a network of exchanges, and a rich and diverse ecosystem of experts, startups, alliance partners, and Capgemini’s own capabilities, to deliver the pinnacle innovation engagement experience. ✨ Our delegation, represented by Dr. Pranav Karmwar and Ms. Mytreyi Kuncham, showcased our in silico solutions for generics and drug discovery. We had the privilege of engaging with key #industry leaders from Sanofi, J&J, DRL, Bharat Tech, GSK, Novartis, and other prominent #pharmaceutical companies. 🏢 The event facilitated invaluable discussions on accelerating #drugdiscovery and development through Computational Modeling & Simulation (CM&S) and Artificial Intelligence (AI) technologies. As a leader in #AI-driven drug discovery, we are proud to contribute to the #advancement of Life Sciences 5.0. 📈 🤝 We extend our sincere gratitude to Capgemini AIE for this incredible #opportunity and look forward to continuing #collaborations with industry leaders to enhance patient #health outcomes. To learn more about our #innovative solutions and how we're #transforming the pharmaceutical landscape, visit www.insilicominds.com 👆 InSilicoTrials #LifeSciences #Innovation #DrugDiscovery #Generics #InSilicoSolutions #CapgeminiAIE #PharmaTech #Biotechnology 

In the fast-evolving world of #drugdiscovery, in silico methods dramatically transform how we identify therapeutic targets. Using comparative #genomics and #network-based approaches, we can accurately pinpoint pathogen-specific targets and map out complex #biological interactions. 🦠 💻 These advanced techniques are not just reshaping how we approach drug discovery; they drive innovation in previously unimaginable ways. By integrating large-scale datasets and #computational tools, we are overcoming traditional challenges like high #costs, lengthy #timelines, and low #success rates in target identification, paving the way for next-generation therapies. ✨ InSilicoMinds expertise in leveraging in silico approaches empowers pharmaceutical companies to accelerate their drug discovery processes, making the journey from lab to patient #faster, more #efficient, and more #effective. InSilicoTrials #InSilicoMinds #DrugDiscovery #Bioinformatics #Pharmaceuticals #PersonalizedMedicine #Biotechnology #CADD

𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐚𝐧𝐝 𝐌𝐚𝐭𝐞𝐫𝐢𝐚𝐥 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐰𝐢𝐭𝐡 𝐂𝐨𝐦𝐩𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐌𝐨𝐝𝐞𝐥𝐢𝐧𝐠 𝐚𝐧𝐝 𝐒𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐏𝐨𝐥𝐲𝐦𝐞𝐫𝐬 💊💻 Polymers play a crucial role in #pharmaceuticals, especially in drug delivery systems. They are used to develop controlled-release #formulations, #biodegradable implants, and more. Designing polymers with specific properties, such as biocompatibility and biodegradability, is essential for creating #safer and more #effective therapies.   ✨ At InSilicoMinds, our in silico #solutions leverage Computational Modeling & Simulations to advance polymer #science. We utilize these approaches to study interactions at the molecular level, predict material properties, and design innovative polymer-based drug delivery systems. Our interdisciplinary team of #chemists, #biologists, and #computational scientists collaborate to accelerate the development of new materials and therapies. Join us in shaping the future of pharmaceuticals. 🤝 InSilicoTrials #ComputationalModeling #DrugDelivery #InSilicoMinds #BiocompatibleMaterials #PolymerScience

Atal Incubation Centre - CCMB, partnered with Central Drugs Standard Control Organization (CDSCO), FDA India, Ministry of Health and Family Welfare, Government of India & Indian Council of Medical Research (ICMR) to host a workshop on “𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗜𝗻 𝗩𝗶𝘁𝗿𝗼 𝗠𝗲𝘁𝗵𝗼𝗱𝘀 𝗮𝗻𝗱 𝗖𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗕𝗶𝗼𝗹𝗼𝗴𝘆”, focusing on recent scientific and regulatory advances in these fields. 🇮🇳 The day-long workshop, attended by nearly 40 regulators and representatives from ICMR, Biotechnology Industry Research Assistance Council (BIRAC), & Humane Society International India (HSI), proved an insightful, first-of-its-kind interaction with drug regulators in #India. The session on 𝗖𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴 & 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗖𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲 & 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀 was a key highlight, featuring talks by Dr. Tausif Ahmed from Dr. Reddy's Laboratories, Mr. Nirnith Devireddy, and Dr. Pranav Karmwar from InSilicoMinds. We delved into the integration of computational tools in regulatory processes, showcasing their importance in drug safety and efficacy assessments. ✨ The workshop also featured sessions on translational advances in stem cell biology, industrial adoption of 𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗜𝗻 𝗩𝗶𝘁𝗿𝗼 𝗠𝗼𝗱𝗲𝗹𝘀 (𝗖𝗜𝗩𝗠), and their standardization, qualification, and validation. These sessions were led by experts like Dr. Sujata Mohanty from AIIMS (All India Institute of Medical Sciences, New Delhi), Dr. Kasturi Mahadik from Atal Incubation Centre - CCMB, and Dr. Viraj Mehta from Sai Life Sciences Ltd, highlighting the cutting-edge research and its practical applications in #drugdevelopment. 🧪 A brainstorming activity titled "𝗥𝗼𝗮𝗱𝗺𝗮𝗽 𝘁𝗼 𝘁𝗵𝗲 𝗮𝗱𝗼𝗽𝘁𝗶𝗼𝗻 𝗼𝗳 𝗡𝗲𝘄 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗠𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗲𝘀 (𝗡𝗔𝗠𝘀)" encouraged interactive discussions among CDSCO regulators, ICMR, DBT/BIRAC, & Industry. Notable remarks were made by Dr. Anita Krishnan from Biocon Biologics and Dr. Kasinath Viswanathan PhD from Zydus Group, providing valuable insights into the #future of NAMs. 📈 Dr. Rajeev Raghuvanshi from Indian Pharmacopoeia Commission (CDSCO) also contributed significantly to the discussions, emphasizing CDSCO's commitment to human-relevant #research and #regulatory advancements. 🧑🔬 The concluding remarks and reflections on the way forward were shared by Dr. Sonia Gandhi from Biotechnology Industry Research Assistance Council (BIRAC) and Dr. Annam Visala from CDSCO, emphasizing the collaborative efforts needed to advance human-relevant biology. 🧬 We are grateful for the support and participation of all the esteemed speakers and organizations. This workshop marks a significant step towards fostering innovation and regulatory excellence in India’s biopharmaceutical landscape. 🤝 CPHMS | Centre for Predictive Human Model Systems #Biotechnology #ComputationalBiology #BiotechInnovation #HealthTech #GovtOfIndia #PharmaIndustry #Biopharmaceuticals

𝐈𝐧𝐬𝐩𝐢𝐫𝐢𝐧𝐠 𝐝𝐢𝐬𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬 𝐚𝐭 𝐭𝐡𝐞 𝟕𝟑𝐫𝐝 #𝐈𝐏𝐂-𝟐𝟎𝟐𝟒! ✨ The 𝗜𝗻𝗱𝗶𝗮𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 (𝗜𝗣𝗖) 𝟮𝟬𝟮𝟰 hosted by the #IPA - Indian Pharmaceutical Association, is a yearly scientific program that aims to expand the horizons of #pharmacetuicals by bringing together renowned researchers, industry leaders, & bright minds to explore growing themes and ideas. The 2024 edition was focused on the Role of Indian Pharma for Global well-being, offering captivating discussions and innovative approaches to building powerful foundations for the future. The colloquium ventured through ideas on HealthCare revolutions and #AI, cutting-edge #pharmaceutical research, drug repurposing, academic evolutions, and #growth in patient care. Mr. Jayapal Reddy Thumma and Mr. Anand Aggala mediated the event, fostering collaborations and vibrant discussions. Our CEO Mr. Nirnith Devireddy and CSO Dr. Pranav Karmwar illustrated the future of AI Modeling & Simulation in #pharmaceutical development. Their #insights highlighted how AI-driven technologies are shaping drug discovery, optimizing processes, and advancing personalized medicine. With the aim to enhance global #healthcare outcomes leveraging pioneering therapies, passionate perspectives and limitless possibilities blossomed to unlock the potential of AI. InSilicoMinds, a leading provider of AI-powered Modelling & Simulation solutions for #pharmaceutical development, is well-positioned to #support your organization in navigating this rapidly evolving landscape. Our team of experts has decades of experience in modeling and simulations for #drugdevelopment and #regulatory compliance. By partnering with us, you can gain a competitive edge, #accelerate your drug development timelines, and ultimately improve patient outcomes #worldwide. InSilicoTrials #InSilicoModeling #RegulatoryAffairs #DataScience #ArtificialIntelligence #LifeSciences #Biotech #Pharma

𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐝𝐫𝐮𝐠 𝐝𝐨𝐬𝐚𝐠𝐞𝐬 𝐢𝐬 𝐚 𝐦𝐮𝐥𝐭𝐢-𝐟𝐚𝐜𝐞𝐭𝐞𝐝 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 𝐝𝐮𝐞 𝐭𝐨 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐱 𝐧𝐚𝐭𝐮𝐫𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫. Tumor heterogeneity, patient variability, and the intricacies of combination therapies add layers of complexity. Traditional methods often fall short, creating a need for innovative solutions. 🏥Collaborations like those between the FDA and International Society of Pharmacometrics (ISoP) underscore commitment to pioneering solutions that ensure efficacy and safety in cancer therapeutics by recommending modeling and simulation as essential approaches to tackle these #challenges effectively. 💻 Integrating preclinical evidence, pharmacodynamic markers, and advanced modeling, we optimize drug dosages and provide comprehensive #solutions that account for the multi-dimensional aspects of dose finding. Our innovative approach ensures #efficacy and #safety in cancer therapeutics, addressing the intricate challenges of dosage #optimization. 💊 ✨ Unlock the future of oncology with InSilicoMinds. Our modeling and simulation techniques enable precise dosage optimization, enhancing patient outcomes and advancing therapeutic efficacy. 🤝 Partner with InSilicoMinds to harness the power of in silico methods and drive innovation in oncology drug development.  InSilicoTrials #Oncology #DrugDevelopment #InSilico #CancerTreatment #DosageOptimization #HealthcareInnovation #Pharmaceuticals #Biotechnology

𝙱𝚒𝚘𝚎𝚚𝚞𝚒𝚟𝚊𝚕𝚎𝚗𝚌𝚎 𝚠𝚒𝚝𝚑 𝙸𝚗 𝚂𝚒𝚕𝚒𝚌𝚘 𝙰𝚙𝚙𝚛𝚘𝚊𝚌𝚑𝚎𝚜 🔬💊 𝗔𝗿𝗲 𝘆𝗼𝘂𝗿 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗕𝗶𝗼𝗲𝗾𝘂𝗶𝘃𝗮𝗹𝗲𝗻𝗰𝗲 (𝗕𝗘) 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝗳𝗮𝗹𝗹𝗶𝗻𝗴 𝘀𝗵𝗼𝗿𝘁? Standard BE evaluation faces significant #challenges: prolonged study durations, increased costs, and complex designs, especially for #drugs with long half-lives, highly variable drugs (HVD), and special formulations. These hurdles can compromise the #efficiency and #accuracy of BE studies, impacting drug approval and patient access to #generics.   Bioequivalence refers to the comparison between a generic drug and a brand-name drug to ensure they have the same #bioavailability and #therapeutic effect. Accurate BE studies are essential to confirm that the generic version performs similarly to its branded counterpart, ensuring #safety and #efficacy for patients. 💻 𝗕𝗘 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗜𝗻 𝗦𝗶𝗹𝗶𝗰𝗼 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 In silico approaches address many challenges of #traditional BE studies. These methods effectively handle sparse #data, separate sources of variability, and increase study power and efficiency. By optimizing study designs and employing advanced simulations, in silico methods enhance the #robustness and #accuracy of BE evaluations, especially for highly variable drugs and special formulations.   ✨ Transitioning to in silico approaches is not just a technological upgrade; it's a paradigm shift that ensures safer, more effective treatments. InSilicoMinds is at the forefront of this revolution, driving advancements in pharmacometrics and bioequivalence. 🤝 Join us in exploring the #future of BE studies and discover how #insilico methodologies can transform #pharmaceuticalresearch. InSilicoTrials #Bioequivalence #Pharmacokinetics #InnovativeSolutions #DrugDevelopment #Bioavailability #Pharmacometrics #BEStudies #ClinicalTrials #PatientSafety #FDAApproval